Iridian Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-935,398
| Closed | -$64.9M | – | 75 |
|
|
2018
Q3 | $64.9M | Buy |
935,398
+74,487
| +9% | +$5.16M | 0.65% | 46 |
|
|
2018
Q2 | $65.1M | Sell |
860,911
-12,220
| -1% | -$925K | 0.6% | 52 |
|
|
2018
Q1 | $46M | Sell |
873,131
-28,566
| -3% | -$1.51M | 0.41% | 53 |
|
|
2017
Q4 | $48.2M | Buy |
901,697
+87,483
| +11% | +$4.67M | 0.41% | 53 |
|
|
2017
Q3 | $48.6M | Buy |
814,214
+119,327
| +17% | +$7.12M | 0.41% | 52 |
|
|
2017
Q2 | $54.8M | Sell |
694,887
-60,140
| -8% | -$4.74M | 0.48% | 54 |
|
|
2017
Q1 | $62.6M | Buy |
755,027
+715,382
| +1,804% | +$59.3M | 0.56% | 54 |
|
|
2016
Q4 | $3.15M | Buy |
39,645
+12,500
| +46% | +$992K | 0.03% | 60 |
|
|
2016
Q3 | $1.9M | Buy |
27,145
+6,580
| +32% | +$461K | 0.02% | 61 |
|
|
2016
Q2 | $798K | Buy |
+20,565
| New | +$798K | 0.01% | 61 |
|